Notably, the acetylation-defective mutant p53 3 KR, which cannot induce cell-cycle arrest, senescence or apoptosis, fully retains the ability to suppress SLC7A11 and trigger ferroptosis under oxidative stress (Le et al., 2015)
Finally, the expanded indication landscape suggests that the GLP-1 platform will increasingly compete not just within obesity, but across MASH, cardiovascular protection, and potentially other metabolic conditions
GLP-1-based therapy supports weight loss by helping regulate appetite and blood sugar signals
NOT Cost-Effective For Insurance-covered patients: Don't pay $300/month cash when insurance covers standard GLP-1s at $25-$100 copays
For example, Mayo Clinic suggests that smoking, pollutants and extreme temperature may contribute to L-C19 pulmonary symptoms persistence (39)